Advicenne: Official Reimbursement of Sibnayal® for the Treatment of dRTA in France

PARIS--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) is now reimbursed by the French social security system for the treatment of distal Renal Tubular Acidosis (dRTA).

The price of Sibnayal® in France for this indication, as published in the Official Journal, is:

- €213.41 including tax for Sibnayal® 24 mEq 847mg/1582 mg
- €71.46 including tax for Sibnayal® 8 mEq 282 mg/527 mg

The publication of the reimbursement decision ends the early access program and makes the dispensing of Sibnayal® directly in retail pharmacies possible.

Didier Laurens, Chief Executive Officer of Advicenne, stated: "We have finally reached an agreement on the reimbursement of Sibnayal® after several years of discussions. It is important that this product, developed in France, manufactured in France, and supported overwhelmingly by French investors, will now be made available to French patients in a simplified manner. We are thinking in particular of patients suffering from dRTA and treated with Sibnayal®, who will be able to access their treatment more easily through the French pharmacy network."

* *
*

About Advicenne

Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.

For additional information, see: https://advicenne.com/.

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.